Enemsa Pharma

Enemsa Pharma is a privately held biopharmaceutical company based in Nantes, France. The company is developing innovative oral small-molecule compounds for neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), Charcot-Marie-Tooth disease (CMT), and Parkinson’s Disease (PD), with a Phase 2 trial already completed for ALS for the most advanced program.

The compound features a unique triple mechanism of action (MOA):
- Blockade of excitotoxicity through selective antagonism of NR2B-containing NMDA receptors;
- Enhancement of the Integrated Stress Response (ISR) by inhibiting eIF2α dephosphorylation; and
- Inactivation of CHOP by maintaining pAMPK activity through the inhibition of PP2A holoenzyme formation.

This multi-pronged approach is expected to robustly support neuronal survival and prevent apoptosis.